Samuel Huse

Samuel Huse

Auto-generated profile, based on publicly available information

Samuel Huse

Evidera

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2025 in Postgraduate Medicine
Verified
Journal Article
Open access
ARAleksandrina Ruseva
Aleksandrina Ruseva
FDFiras Dabbous
Firas Dabbous
NDNina Ding
Nina Ding
AFAnthony Fabricatore
Anthony Fabricatore
SHSamuel Huse
Samuel Huse
DUDevika Umashanker
Devika Umashanker
To evaluate the effectiveness of semaglutide 2.4 mg for weight reduction and improvement in cardiometabolic biomarkers at 52 and 68 weeks in a real-world setting in the United States. This noninterventional, retrospective cohort study used the Komodo Health database and included adults with obesity or overweight with ≥ 1 weight-related condition who initiated treatment with semaglutide 2.4 mg between June 2021 and August 2022 and remained on treatment for 1 year. A paired t-test was used to assess changes in weight, body mass index (BMI), and cardiometabolic biomarkers (systolic blood pressure [SBP], diastolic blood pressure [DBP], glycated hemoglobin [HbA1c], HDL [high-density lipoprotein] cholesterol, LDL [low-density lipoprotein] cholesterol, and triglycerides) from baseline to 52-week and 68-week follow-up. Among 4,424 eligible patients, 77% were women and the mean (SD) age was 46.7 (10.0) years and BMI was 36.6 (3.6) kg/m2. Dyslipidemia and hypertension were the most common obesity-related comorbidities at baseline. The mean (%) change in weight from baseline was -15.5 kg (-14.5%; p < 0.001; n = 594) at 52 weeks and -15.9 kg (-14.8%; p < 0.001; n = 391) at 68 weeks. The mean change in BMI from baseline was -4.8 kg/m2 (n = 1124) at 52 weeks and -4.9 kg/m2 (n = 700) at 68 weeks. At 52-weeks, statistically significant improvements in mean values were observed for SBP (-6.3 mmHg), DBP (-3.1 mmHg), HbA1c (-0.4%), LDL cholesterol (-8.1 mg/dL), and triglycerides (-38.4 mg/dL) (all p < 0.001). Mean change at 52 weeks for HDL cholesterol was 1.0 mg/dL; p = 0.109. Results at 68 weeks were similar. In this retrospective cohort study, the real-world effectiveness of semaglutide 2.4 mg was demonstrated by reductions in weight and BMI along with improvements in BP, HbA1c, and lipid panel among patients with obesity or overweight.

19 March 2025 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
OHOscar Herrera-Restrepo
Oscar Herrera-Restrepo
MKMarta Kwiatkowska
Marta Kwiatkowska
SHSamuel Huse
Samuel Huse
NNNelson Ndegwa
Nelson Ndegwa
ZKZeki Kocaata
Zeki Kocaata
MGMichael L. Ganz
Michael L. Ganz
In the United States, while meningococcal vaccines are available and recommended for adolescents and young adults, coverage remains low and disparities persist. We evaluated meningococcal serogroups A, C, W, Y (MenACWY) and B (MenB) vaccine uptake, completion, and compliance using a cross-sectional analysis of National Immunization Survey-Teen (NIS-Teen) data (2015-2021) and a cohort analysis of commercial claims data (2010-2021). Regression models were used to identify factors associated with vaccine uptake. Included in the NIS-Teen MenACWY and MenB analyses were 138,952 and 177,077 patients, respectively. Included in the claims MenACWY and MenB analyses were 953,905 and 818,424 patients, respectively. In 2021, MenACWY uptake was 86.4% (95% confidence interval [CI]: 83.6-88.8%) among ≤13-year-olds (NIS-Teen) and 63.2% (62.8-63.5%) among 11-12-year-olds (claims). MenB was 33.7% (30.5-37.1%) among ≤17-year-olds (NIS-Teen), 41.6% (41.2-42.0%) among 16-18-year-olds (claims), and 15.0% (14.7-15.4%) among 19-23-year-olds (claims). The states with the lowest and highest MenB uptake by ≤17-year-olds in 2021 (NIS-Teen) were Minnesota (10.1% [3.9-23.6%]) and North Dakota (69.9% [52.1-83.2%]). Factors associated with MenACWY uptake included living in a state with a vaccine mandate, Black or Hispanic race (versus White), and well-child visit attendance. Factors associated with MenB uptake included having Medicaid (versus private insurance) and Hispanic race (versus White). The findings suggest that meningococcal vaccination coverage disparities persist across vaccines, age, geography, and race and ethnicity. Higher MenACWY (versus MenB) coverage suggests the benefit of routine recommendations. Annual well-child visits and simplified vaccination schedules could reduce vaccination access barriers.

16 December 2024 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
OHOscar Herrera-Restrepo
Oscar Herrera-Restrepo
MKMarta Kwiatkowska
Marta Kwiatkowska
SHSamuel Huse
Samuel Huse
ZKZeki Kocaata
Zeki Kocaata
MGMichael L. Ganz
Michael L. Ganz
Invasive meningococcal disease (IMD) is a life-threatening yet vaccine-preventable disease, with vaccines approved and recommended in the United States by the Centers for Disease Control and Prevention. This study assessed complications, mortality, healthcare resource utilization (HCRU), and healthcare costs among a sample of commercially-insured individuals living in the United States who experienced IMD. We used retrospective data from large claims databases limited to individuals with IMD covered by commercial health plans between January 2010–March 2022. Health outcomes, HCRU, and healthcare costs were analyzed during the acute (index date to 30 days post-hospital discharge) and post-acute (end of acute phase to end of follow-up period) phases. Among 618 IMD cases identified, the most common acute phase complications were severe brain damage, renal failure, and autoimmune disease. The most common post-acute phase complications were autoimmune disease, arthralgia, and renal failure. Acute phase HCRU ranged from 72.7 (95% confidence interval [CI] 19.81–186.12) intensive care unit (ICU) stays to 12,102.9 (95% CI 11,201.07–13,058.00) surgeries per 1,000 patient-years. Post-acute phase HCRU ranged from 3.6 (95% CI 1.18–8.50) ICU stays to 7,808.3 (95% CI 7,661.22–7,957.54) specialty physician visits per 1,000 patient-years. Patients with IMD incurred average healthcare costs of $60,866.23 and $145,883.65 during the acute and post-acute phases, respectively. Negative health outcomes and high HCRU and costs were observed among commercially-insured patients with IMD. Our findings suggest that IMD immunization efforts and healthcare interventions targeting education on vaccine recommendations to healthcare providers and patients could help prevent IMD and reduce disease burden.

6 January 2026 in Journal of the American Heart Association
Verified
Journal Article
Open access
BSBenjamin A. Steinberg
Benjamin A. Steinberg
FDFiras Dabbous
Firas Dabbous
RPRon Preblick
Ron Preblick
DSDivya Shridharmurthy
Divya Shridharmurthy
DMDavid S. McKindley
David S. McKindley
JSJagmeet P. Singh
Jagmeet P. Singh
Background: This retrospective observational study compared adverse events (AEs) and health care resource use among patients with atrial fibrillation treated with dronedarone versus amiodarone. Methods: Adults with atrial fibrillation who initiated dronedarone or amiodarone between January 1, 2010 and September 30, 2021 were propensity score matched in Optum’s deidentified Clinformatics Data Mart Database. Outcomes included AEs (described in the dronedarone/amiodarone Food and Drug Administration labels and reported in the Food and Drug Administration AE Reporting System) and all‐cause and cardiovascular‐related health care resource use. Generalized linear models with Poisson distribution were used to compare the risk of AEs between the 2 cohorts. After matching, 12 210 dronedarone‐treated patients were paired 1:1 with amiodarone‐treated patients. For each AE, patients who experienced the AE during baseline were excluded. Results: During follow‐up, lower event rates of AEs were observed with dronedarone versus amiodarone; the rate ratio for any cardiac and vascular AE was 0.71 (95% CI, 0.69–0.72), any respiratory AE was 0.65 (95% CI, 0.63–0.66), and any gastrointestinal/hepatobiliary AE was 0.81 (95% CI, 0.79–0.84). Compared with amiodarone‐treated patients, dronedarone‐treated patients experienced lower event rates of all‐cause hospitalization (0.69 [95% CI, 0.67–0.71]) and all‐cause outpatient visits (0.87 [95% CI, 0.87–0.87]). Although the incidence of cardiovascular‐related hospitalization was higher with dronedarone versus amiodarone, event rates were not statistically different. Cardiovascular‐related outpatient visits were significantly reduced with dronedarone versus amiodarone with an event rate of 0.95 (95% CI, 0.94–0.96). Conclusions: In this study, lower event/incidence rates of AEs and health care resource use were observed in patients with atrial fibrillation treated with dronedarone versus amiodarone.

2 November 2025 in Current Medical Research and Opinion
Verified
Journal Article
Open access
HAHusam Albarmawi
Husam Albarmawi
FDFiras Dabbous
Firas Dabbous
AAAbdalla Aly
Abdalla Aly
AYAlia Yousif
Alia Yousif
SHSamuel Huse
Samuel Huse
ELEric Lawitz
Eric Lawitz
In the phase 3 ESSENCE clinical trial, semaglutide demonstrated improved histological outcomes for patients with metabolic dysfunction-associated steatohepatitis (MASH) with moderate or advanced fibrosis. There is limited real-world evidence regarding the effect of semaglutide on liver enzymes and cardiometabolic markers in routine clinical practice. This retrospective cohort analysis used linked administrative claims and laboratory data from December 2020 to November 2024 and included patients with MASH and either overweight or obesity. We compared patients initiating semaglutide and those not using anti-obesity medications (comparator) in terms of changes in liver enzymes (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) and other laboratory markers, including body weight, Hemoglobin A1c (HbA1c), and lipids. Absolute and percent change from baseline was reported for each outcome at 6 months. Dependent within-group comparisons were computed using paired t-tests. To compare the change in ALT and AST between the comparison groups, difference in differences (DiD) estimates were calculated using generalized linear models adjusting for baseline characteristics. We identified 4,124 individuals initiating semaglutide and 168,284 individuals not using anti-obesity medications. Those receiving semaglutide were younger, more often female, and had fewer cardiometabolic comorbidities. Patients on semaglutide with available liver enzyme data experienced a 36% reduction in ALT (mean decrease: 19.4 U/L; p < 0.01; N = 27) and a 29% reduction in AST (mean decrease: 10.9 U/L; p = 0.01; N = 29). The comparator group experienced a 7% reduction in ALT (mean decrease: 2.8 U/L; p < 0.01; N = 2,680) and a 5% reduction in AST (mean decrease: 1.7 U/L; p < 0.01; N = 2,699). Comparing the changes in ALT and AST between the two comparison groups, the semaglutide group showed a greater reduction in ALT (DiD: -15.9; 95% CI: -27.5 to -4.2; p = 0.01) and trend towards greater reduction in AST (DiD: -8.7; 95% CI: -18.5 to 1.2; p = 0.08). The semaglutide groups demonstrated a 5.3% reduction in body weight and a 5.4% decrease in Hemoglobin A1c (both p < 0.01), while the comparator groups showed a 0.3% weight loss (p < 0.01) and no change in Hemoglobin A1c. In patients with MASH and either overweight or obesity, semaglutide was associated with a clinically and statistically significant reduction in ALT after 6 months of continuous use. Reductions in AST, weight, and HbA1c were also observed.